Introduction
============

Gastric cancer is a malignant disease with high incidence and mortality rates, particularly in Asian populations ([@b1-ol-07-04-1021],[@b2-ol-07-04-1021]). The oncogenesis and development of gastric cancer are influenced by genetic and epigenetic factors. DNA methylation is the most studied epigenetic mechanism. At present, the focus of the majority of studies is the inactivation of gene expression by hypermethylation of DNA located in tumor suppressor gene promoter regions. The observation that promoter CG island methylation inactivates a number of tumor suppressor genes in gastric cancer, such as *RASSF1A, P16 a*nd *E-cadherin*, has increased the understanding of the mechanism of gastric carcinogenesis ([@b3-ol-07-04-1021]). For technical reasons, the majority of previous studies have focused on only a few genes. With the development of sequencing and microarray technology, a large-scale study of the pattern of DNA methylation, which is also called the methylome, became possible ([@b4-ol-07-04-1021],[@b5-ol-07-04-1021]). The present study analyzed DNA methylation characteristics of the gastric cancer genome using the Infinium 450K methylation microarray to further understand the pathogenesis of gastric cancer and identify potential therapeutic targets and diagnostic markers for gastric cancer.

Materials and methods
=====================

Clinical samples
----------------

In total, 40 patients with gastric cancer from the Wuhan General Hospital of the Guangzhou Command (Wuhan, China) during the period between March 2011 and June 2012 were included. Each tumor sample was matched with adjacent apparently normal mucosa (3--5 cm from the tumor margin) removed during the same surgery. All samples were collected by one surgical pathology fellow from the operating room immediately following the surgical resection and frozen in the liquid nitrogen. Pathological diagnosis was determined independently by two pathologists and disagreement was resolved by consensus. The study protocol was approved by the ethics committee of Wuhan General Hospital of Guangzhou Command (Wuhan, China).

Genomic DNA extraction and quality control
------------------------------------------

DNA was extracted from \~25 mg of tissue using a DNA extraction kit (Quick-gDNA MiniPrep; Zymo Research Corporation, Orange, CA, USA) according to the manufacturer's instructions, and DNA quality was assessed using spectrophotometry (UV-100, Shanghai Precision Instrument Co., Ltd., Shanghai, China) and agarose gel electrophoresis (Amresco LLC, Solon, OH, USA).

DNA methylation profiling with Infinium 450K methylation assay
--------------------------------------------------------------

In total, six paired samples were processed on the chip (12 samples/chip). Genomic DNA (500 ng) was treated with sodium bisulfite using the Zymo EZ DNA Methylation Kit™ (Zymo Research Corporation) according to the manufacturer's instructions, with the alternative incubation conditions recommended for the Illumina Infinium 450K methylation assay (Illumina Inc., San Diego, CA, USA). The methylation assay was performed on 4 μl of bisulfite-converted genomic DNA at 50 ng/μl according to the Infinium HD methylation assay (Illumina Inc.) instructions. The quality of the results was assessed using the GenomeStudio™ Methylation Module v1.8 software (Illumina, Inc., San Diego, CA, USA) and all samples passed this quality control. β-values were extracted using the same software.

Bisulfite pyrosequencing
------------------------

A total of six CpGs sites were selected for technical validation of Infinium 450K methylation by the bisulfate pyrosequencing technique on 40 paired samples (cancer and normal tissues). One candidate site in each of the five genes (*TRIM15, ITGAM, SLMO2, MSX2* and *FAM38A*) was selected and all were located in the gene body. Primers for polymerase chain reaction (PCR) amplification and sequencing were deduced using the PyroMark Assay Design 2.0 software (Qiagen, Hilden, Germany) and all primer sequences are shown in [Table I](#tI-ol-07-04-1021){ref-type="table"}. Bisulfite conversion of genomic DNA was performed, followed by PCR. PCRs were performed under the following conditions: 95°C for 15 min; 45 cycles of 94°C for 30 sec, 56°C for 30 sec, 72°C for 30 sec; and 72°C for 10 min. The success of amplification was assessed by agarose gel electrophoresis and pyrosequencing of the PCR products was performed using the PyromarkID system (Qiagen). Only blue values (perfect calls) were considered for subsequent analyses.

RNA extraction and quantitative PCR (qPCR)
------------------------------------------

Total cellular RNA was extracted using the TRIzol method. RNA quality was assessed by spectrophotometry and agarose gel electrophoresis. A total of 5 μg of RNA was reverse transcribed using the All-in-One™ First Strand cDNA synthesis kit (AORT-100; GeneCopoeia™, Rockville, MD, USA). Quantitative qPCR amplification reactions were performed using the All-in-One qPCR master mix (AOPR-1200; GeneCopoeia) with a Real-Time PCR system (ABI StepOne plus; Applied Biosystems, Carlsbad, CA, USA). The expression levels of the genes were normalized to the expression of actin. Primer sequences and PCR conditions are shown in [Table II](#tII-ol-07-04-1021){ref-type="table"}.

Bioinformatics analysis
-----------------------

Integrated gene ontology and pathway analysis database MAS3.0 (<http://www.capitalbio.com>) were to investigate potential molecular function and the pathway of the candidate biomarkers.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA). Group comparisons were performed using a paired samples t-test. Two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Patients
--------

The present study was conducted on 40 patients (23 male and 17 female) with gastric cancer, with a mean age of 56 years. The methylation microarray procedure was performed on specimens from six patients. The tumors were all adenocarcinomas.

Pyrosequencing
--------------

Pyrosequencing was performed on specimens from 40 patients. In total, 2,645 methylation differential sites (covering 1,352 genes) were detected in the gastric cancer tissues compared with the normal tissues. In the gastric cancer tissue, 2,016 sites (covering 1,008 genes) were hypermethylated and 629 sites (covering 344 genes) were hypomethylated ([Table III](#tIII-ol-07-04-1021){ref-type="table"}). From the functional genome distribution standpoint, 824 sites (31%) were located in promoters and 1,026 sites (39%) are located in the gene body. In addition, 91 sites (3%) and 704 sites (27%) corresponded to the 3′-untranslated regions and intergenic sequences, respectively. From the CpG content and neighborhood context, 736 CpG sites (28%) were in CpG islands, 463 (17%) were in CpG shores, 228 (9%) were in CpG shelves and 1,218 (46%) were in the 'open sea' (isolated CpGs in the genome). The methylation differential sites were distributed among all 22 autosomal chromosomes and one sex chromosome. The majority of positions were harbored in chromosome one (9.1%), followed by chromosomes two (8.9%) and six (7.7%). The distribution of these sites is shown in [Figs. 1](#f1-ol-07-04-1021){ref-type="fig"} and [2](#f2-ol-07-04-1021){ref-type="fig"}.

Gene regulation
---------------

A total of 979 genes were upregulated and 314 genes were downregulated in gastric cancer samples compared with the normal samples. Signaling pathway analyses showed that the majority of the genes that were upregulated and downregulated in gastric cancer were involved in the same pathways, including apoptosis, cell cycle, ErbB, Janus kinase-signal transducer and activator of transcription, mitogen-activated protein kinases, p53, transforming growth factor-β, Toll-like receptor, vascular endothelial growth factor and Wnt signaling pathways. We proposed that these pathway alterations may be associated with the clinical pathological features and outcome of GC patients. An integrated gene ontology database was used to annotate the molecular function of the differentially expressed genes. The results showed that genes that were upregulated and downregulated in gastric cancer were involved in the majority of the important biological process associated with human cancer, including regulation of the inhibitor-κB kinase/nuclear factor-κB cascade, cell differentiation, cell cycle arrest, caspase activation and cell proliferation ([Table IV](#tIV-ol-07-04-1021){ref-type="table"}).

Methylation levels
------------------

In total, five differential sites (*TRIM15, ITGAM, SLMO2, MSX2* and *FAM38A*) were selected and verified in 40 samples by pyrosequencing. The mean methylation levels of gastric cancer tissues were higher than those of normal gastric tissues for two sites (*TRIM15* and *ITGAM*) and lower for two sites (*MSX2* and *FAM38A*), which were consistent with the results of the microarray analysis. The mean methylation level of *SLMO2* was not different between normal and cancer tissues ([Table V](#tV-ol-07-04-1021){ref-type="table"}, [Fig. 3](#f3-ol-07-04-1021){ref-type="fig"}).

Transcriptional levels
----------------------

To examine the transcriptional level of the four genes (T*RIM15, IGTAM, MSX2* and *FAM38A*), qPCR was performed using primers specific for these genes. qPCR results showed that the expression levels of ITGAM, MSX2 and FAM38A were upregulated in gastric cancer tissues, while the expression level of TRIM15 was downregulated (P\<0.05).

Discussion
==========

DNA methylation is important in the development of gastric cancer. Previously, it has been found that hypermethylation inactivates a number of gene promoters. However, previous studies have been limited by technology that only allows analysis of a few genes. In addition, the majority of studies have paid close attention to the CpG island in the promoter region. According to current knowledge, only a few CpG dinucleotides have been identified at the promoter CpG islands, mostly scattered in the genome. In tumorigenesis, the importance of scattered CpG dinucleotide methylation remains poorly understood ([@b6-ol-07-04-1021],[@b7-ol-07-04-1021]). Therefore, understanding genome-wide DNA methylation changes is necessary for the in-depth investigation of tumor occurrence.

The latest generation of methylation microarrays includes the Infinium 450K methylation microarray. This microarray detects \>450,000 methylation sites per sample. It includes methylation regions, such as CpG islands, CpG shores, CpG sites outside of CpG islands, non-CpG methylated sites identified in human stem cells, differentially methylated sites identified in tumor versus normal tissues (multiple forms of cancer), across several tissue types, CpG islands outside of coding regions, miRNA promoter regions and disease-associated regions identified through genome-wide association study ([@b8-ol-07-04-1021]). To date, the Infinium 450K methylation microarray is the most attractive, powerful and cost-effective tool available for generating quantitative DNA methylomes in healthy and diseased individuals ([@b9-ol-07-04-1021],[@b10-ol-07-04-1021]). Using the Infinium 450K methylation microarray, the present study compared the genomic DNA methylation of gastric cancer with that of normal gastric tissue, screened 2,645 differential sites, showed the detailed distribution of these differential sites and established a gastric cancer DNA methylation profile. Verification of the microarray results by pyrosequencing showed that these results were reliable.

A considerable number of differentially methylated sites are located in the promoter region. However, the majority of them appear within the gene body. A number of previous studies have shown abnormal methylation of the CpG island in the promoter region and increasing attention has been paid to methylation of the gene body ([@b11-ol-07-04-1021],[@b12-ol-07-04-1021]). Unlike the correlation between promoter DNA methylation and gene transcription inhibition, the correlation between gene body methylation and gene expression is more complicated. A meta-analysis of this correlation by Jjingo *et al* ([@b13-ol-07-04-1021]) suggested that the gene body DNA methylation is highest when gene expression is moderate. Additionally, when gene expression is high or low, the degree of gene body DNA methylation is extremely low. In the current study of the correlation between methylation changes in four selected differentially methylated sites in the genome and gene expression, the effects of DNA methylation on gene expression varied between genes.

The current study found that the methylation changes in certain genes occurred in multiple sites, some in the promoter and some in the gene itself; certain sites became hypermethylated and others hypomethylated, which suggested that gene expression is regulated by complicated patterns of multi-site methylation. Bioinformatics analysis suggested no difference between genes with hypermethylated sites and genes with hypomethylated sites in associated signaling pathways, which included signaling pathways involved in apoptosis, cell proliferation and cell cycle control.

The present relatively large-scale investigation of methylation changes of gastric cancer, covering a relatively large genomic area, found a number of new differentially methylated sites, including hypermethylation and hypomethylation sites. Analysis of the results identified *TRIM15, ITGAM, MSX2* and *FAM38A* as possible candidate sites clinically useful for the diagnosis and treatment of gastric cancer. In addition, a number of differentially methylated sites were identified in the microRNA gene. Further studies must be performed to explain this phenomenon.
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###### 

Primers for bisulfite pyrosequencing.

  Gene     Sequence                            Nt   Tm, °C   GC, %
  -------- ----------------------------------- ---- -------- -------
  TRIM15   F: GGTTTAATGGTAGGTTGTTTAAGT         24   58.4     33.3
           R: ATATACCTCACTAACTTCCTATCTT        25   58.2     32.0
           S: ATCCAAAATAATAACCCCT              9    45.2     31.6
  ITGAM    F: GTTAAGTGTGGTTTGGGTAGAGTTT        25   59.1     40.0
           R: ACTACTATCCCTCTCACTACCCTCCTCTA    29   60.3     48.3
           S: GGGGATTTTTTTTATTTATTATGTT        25   45.0     20.0
  SLMO2    F: GGGGATGAGTTAGGAAGAAGAGT          23   62.6     47.8
           R: AATCCCATTCATCACTAATCCATTTCAACT   30   58.9     33.3
           S: AGATAGTTTTAGGGAGATTG             20   46.3     35.0
  MSX2     F: GTTTTTAATAGGGTGGAGAGAGATTG       26   60.3     38.5
           R: TACCCCCTAATTTCCCACC              19   58.4     52.6
           S: ATGGTTTTGTTTTGTTAATAAAAT         24   44.2     16.7
  FAM38A   F: TGGGGTTTTTTGATTGTAAAAGT          23   58.3     30.4
           R: CTAAAAAATCTTCCCCAAATTTCACC       26   60.6     34.6
           S: GTTTGTTTGAGGTTTTTAGATA           22   44.1     27.3

F, forward; R, reverse; S, sequence to analyze; Nt, nucleotides; Tm, temperature; GC, gastric cancer.

###### 

Primers for quantitative polymerase chain reaction.

  Gene     Forward primer         Reverse primer          Product, bp   Tm, °C
  -------- ---------------------- ----------------------- ------------- --------
  Actin    GTCCACCGCAAATGCTTCTA   TGCTGTCACCTTCACCGTTC    190           59
  TRIM15   AGCAAGAAGCATCAGGTGGA   GACAAGGTCAGGAGAAATGGC   294           59
  ITGAM    CCTTGTGGTTCCTCAGTGGT   CTTGGAAGGTCATTGCGTTT    154           59
  MSX2     AAGATGGAGCGGCGTGGAT    CGAGGAGCTGGGATGTGGT     138           59
  FAM38A   ATCCACTCCGGGGACTACTT   GGTAGCTGTCCTGCCTGTTC    197           59

bp, base pairs; Tm, temperature.

###### 

Hypermethylated and hypomethylated sites (partly).

  A, Hypermethylated                                    
  -------------------- ----------- -------------------- ------------
  cg08977390           TRIM15      Body                 6
  cg21678445           ZNF521      Body                 18
  cg02256631           ITGAM       Body                 16
  cg01192077           EBF1        Body                 5
  cg18369516           ZBTB46      Body                 20
  cg06445348           ILDR2       Body                 1
  cg18125573           RARA        Body                 17
  cg04407470           NR2E1       Body                 6
  cg22388634           VSX1        Body                 20
  cg14063008           DAB2IP      Body                 9
  cg24171907           CNRIP1      5′UTR                2
  cg16306190           LRRC34      1st exon             3
  cg11595545           KCNA3       1st exon             1
  cg08048222           ZNF671      TSS200               19
  cg09734791           MSC         1st exon             8
  cg25024074           ITGA4       1st exon             2
  cg16964348           NPY         TSS200               7
  cg17508991           HCK         TSS1500              20
  cg18372896           JDP2        5′UTR                14
  cg17219660           GPR37L1     TSS200               1
                                                        
  B, Hypomethylated                                     
                                                        
  Target ID            UCSC name   UCSC refGene group   Chromosome
                                                        
  cg20726575           SLMO2       Body                 20
  cg06013117           MSX2        Body                 5
  cg06007201           FAM38A      Body                 16
  cg21499869           ELL         Body                 19
  cg16499677           C14ORF37    Body                 14
  cg23263641           CADM4       Body                 19
  cg18847089           PRKAR1B     Body                 7
  cg27341866           C19orf35    Body                 19
  cg13826564           LTBP3       Body                 11
  cg04529865           GALNT9      Body                 12
  cg01515802           LATR1       TSS200               19
  cg22888958           CREB5       5′UTR                7
  cg23264429           STAMBPL1    5′UTR                10
  cg19060371           LCP1        5′UTR                13
  cg01318557           LAT2        5′UTR                7
  cg22274117           ATXN1       5′UTR                6
  cg06442489           ZSCAN18     TSS1500              19
  cg02829601           SYTL3       TSS200               6
  cg06523556           CHRNA6      TSS200               8
  cg20117742           LAIR1       TSS200               19

UTR, untranslated region.

###### 

Signaling pathway analyses.

  Pathway              Upregulated                                                                                        P-value    Downregulated                                                                                                       P-value
  -------------------- -------------------------------------------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------------------------------- ----------
  Apoptosis            BCL2, CAPN2, ENDOD1, NFKBIA, NTRK1 and PRKACB                                                      9.77E-04   CASP8, IL1A, IL1B, PRKACA and TNFRSF10A                                                                             4.44E-05
  Cell cycle           ANAPC5, CDH1 and MYT1                                                                              0.193209   CDC2, CDK1 and LAT                                                                                                  0.094077
  ErbB                 CAMK2B, GAB1, GRB2 and NRG2                                                                        0.02511    PRKACA and STAT5A                                                                                                   0.054748
  Jak-STAT             CNTFR, CSF3R, GHR, GRB2, IFNK, IL22RA1, IL2RA, IL7 and PIAS4                                       1.77E-04   IL12B, IL21R, SOCS2, SOCS5 and STAT5A                                                                               5.93E-04
  MAPK                 CACNA2D2, CACNA2D3, DUSP16, FGF12, GNG12, GRB2, MAPKAPK2, MRAS, NTRK1, PDGFA, PRKACB and RASGRF1   2.37E-04   CACNA1C, CACNA1H, CACNA1I, DUSP14, HSPA1A, HSPA1A, IL1A, IL1B, IL1R2, MEF2C, NF1, PRKACA, PRKACA, RPS6KA2 and SCT   1.52E-12
  p53                  SESN1, SESN3 and TSC2                                                                              0.057786   CASP8, CDC2, CDK1 and RRM2                                                                                          0.00338
  TGF-β                BMP2, CHRD, GDF6, SMAD6, SMAD7, SMAD9 and SMURF2                                                   1.25E-04   BMPR1B and INHBA                                                                                                    0.054748
  Toll-like receptor   NFKBIA, TOLLIP and TRAF3                                                                           0.140739   CASP8, IL12B, IL1B and TLR6                                                                                         0.001034
  VEGF                 MAPKAPK2 and NFATC1                                                                                0.251502   NFATC1 and PRKACA                                                                                                   0.043002
  Wnt                  CAMK2B, CTBP2, LRP5, NFATC1, POR, PPP2R5C, PRICKLE1, PRKACE, SFRP1, SOX17, TCF4, WNT11 and WNT6    8.63E-08   APC, NFATC1, PRKACA and PRKACA                                                                                      0.004401

Jak-STAT, Janus kinase-signal transducer and activator of transcription; MAPK, mitogen-activated protein kinases; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor.

###### 

Level of methylation of five sites.

           Level of methylation, %                 
  -------- ------------------------- ------------- ----------
  TRIM15   10.71±3.08                5.86±1.65     \<0.0001
  ITGAM    44.23±17.68               26.34±9.41    \<0.0001
  SLMO2    74.72±17.01               71.73±10.77   0.561
  MSX2     21.34±7.49                38.20±6.49    \<0.0001
  FAM38A   18.21±5.43                32.92±6.71    \<0.0001

GC, gastric cancer.
